Theseus Pharmaceuticals, Inc.·4

Mar 2, 7:00 AM ET

CLACKSON TIMOTHY P 4

4 · Theseus Pharmaceuticals, Inc. · Filed Mar 2, 2023

Insider Transaction Report

Form 4
Period: 2023-03-01
CLACKSON TIMOTHY P
DirectorPresident and CEO
Transactions
  • Award

    Restricted Stock Units

    2023-03-01+45,62545,625 total
    Common Stock (45,625 underlying)
Footnotes (2)
  • [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
  • [F2]The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the RSUs vesting on March 1, 2024 and 1/16th of the RSUs vesting quarterly thereafter, subject to the Reporting Person's continuous service with the issuer. The RSUs have no expiration date.

Documents

1 file
  • 4
    tm237858-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT